Defense News ,U.S :- Emergent BioSolutions, a company in Maryland, has won a contract worth up to $235.8 million to provide anthrax vaccine solutions for the United States military.
For the next five years, Emergent will be supplying its special BioThrax vaccine to the US Department of Defense. This vaccine will be used to protect military personnel from anthrax as a preventive measure before any exposure to the disease.
The contract also includes an option to extend the project until 2033 if needed.
Paul Williams, Senior Vice President at Emergent, expressed pride in the company's mission to safeguard the lives of the nation's service members at high risk of anthrax exposure. He emphasized the significance of Emergent's medical countermeasures portfolio and the commitment to fulfilling their responsibilities to the US Department of Defense.
About Anthrax:
Anthrax is a disease that can be transmitted from animals to humans, posing a threat to health. It can lead to damage to organ systems, inflammation of the brain and spinal cord, and even death.
This harmful bacteria can affect individuals, livestock, and wild game through ingestion, skin contact, and inhalation. Preventive measures, like the BioThrax vaccine, play a crucial role in protecting individuals from the risks associated with anthrax exposure.
——— End of Article ———
